Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY:DGX)

177.83 +0.77 (+0.43%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Opioid Crisis and Corporate Accountability: Purdue's Settlement in the Spotlight
The U.S. Supreme Court is reviewing a contentious bankruptcy settlement involving Purdue Pharma, the maker of OxyContin, and its owners, the Sackler family.  
Via Benzinga
Topics Bankruptcy
Half Of S&P 500 Stocks Still Below 200-Day Average, Ignoring Covid-Like Rally: 10 Bargain Plays For Latecomer Bulls
Explore the dichotomy in the latest S&P 500 rally: Strong overall performance masks the underperformance of nearly half its stocks. 
Via Benzinga
Topics Stocks
Expert Ratings for Quest Diagnostics
Via Benzinga
Firing on All Cylinders Indeed
Investors are seeing some big reactions to earnings results in tech and have a few reasons to think some beaten-up names might be finding their footing. 
Via The Motley Fool
Making Connections To Care: Quest Supports Inspiring Health Equity Event Hosted by Sisters on the Vineyard
Via ACCESSWIRE
Quest Diagnostics: Dividend Insights
Via Benzinga
Analyst Ratings for Quest Diagnostics
Via Benzinga
Quest Diagnostics Q3: 7.7% Topline Decline, Earnings Beat, Updated Guidance & More
Quest Diagnostics Incorporated (NYSE: DGX) posted Q3 FY23 adjusted EPS of $2.22, down 5.9% Y/Y, beating the  
Via Benzinga
Topics Earnings
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... 
Via Benzinga
The Latest Analyst Ratings for Quest Diagnostics
Via Benzinga
Will Chart Analysts Notice Bad Omen on Quest Diagnostics's Chart
Via Benzinga
Quest Diagnostics Q1 Earnings Surpass Expectations; COVID-19 Testing Revenues Slump 80%
Via Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
3 Pharma Stocks to Buy as Summer COVID Cases Spike
Covid cases are on the rise, which might be the booster shot these top pharma stocks for Covid need to regain their trajectory. 
Via InvestorPlace
Why Bionano Genomics Stock Tanked Today
A CFO departure shines a light on some of the company's recent struggles. 
Via The Motley Fool
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Alzheimer's is a huge problem, and earlier detection could make a big difference. 
Via The Motley Fool
Looking for a Bargain? 3 Stocks to Buy That Are Down 10% in 2023
Investors looking for bargain stock opportunities in a rapidly-rising market should consider these companies that haven't yet bounced back. 
Via InvestorPlace
Quest Diagnostics Stock Falls on Lower Q2 Revenue and Profits from Lower Productivity Effects, Tightened Outlook
Quest Diagnostics Inc (NYSE: DGX) posted Q2 FY23 adjusted EPS of $2.30, down 2.5% Y/Y, beating the consensus of $2.27. 
Via Benzinga
Sustaining Growth Momentum: Quest Diagnostics Continues to Excel and Reports Rising Profits
At the end of July 25, 2023, Quest Diagnostics (NYSE:DGX) will reward its shareholders with a dividend payout of $0.71 per share, demonstrating an annualized dividend yield of 2.15%. Remember, only... 
Via Benzinga
Quest Diagnostics, Keysight Technologies And A Stock Up 42% Year To Date On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said he likes Quest Diagnostics Incorporated (NYSE: DGX) here. 
Via Benzinga
Biden Administration Releases Revised Guidance For Medicare Drug Price Negotiation Amid Industry Lawsuits
The Centers for Medicare and Medicaid Services released revised guidance on using its authority with pharmaceutical manufacturers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Via Benzinga
FDA Readies Proposal for Increased Oversight on Lab-developed Tests
The FDA is preparing to increase regulation of a widely used class of tests conducted by laboratories to detect cancer, measure cholesterol, and identify other health issues. The FDA is developing a... 
Via Benzinga
Want Growing Passive Income? Consider Buying This Stock
This maker of diagnostics tests has delivered 13 years of dividend growth to shareholders. 
Via The Motley Fool
Post-Accident Workforce Drug Positivity For Marijuana Reached 25-Year High In 2022, Quest Diagnostics Drug Testing Index Analysis Finds
The percentage of employees in the general U.S. workforce testing positive for marijuana following an on-the-job accident increased to its highest level in 25 years in 2022, according to a new analysis... 
Via Benzinga
Exact Sciences Serves Investors Exactly What They Wished For
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The 
Via MarketBeat
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023
Via Benzinga
UiPath is a Cheaper and More Profitable AI Stock
With the mainstream popularity of ChatGPT, artificial intelligence (AI) has been all the rage in 2023. The AI wars between Microsoft Co. (NASDAQ: MSFT) invest 
Via MarketBeat
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.